Matinas biopharma reports fourth quarter and full year 2021 financial results and operational highlights

– fifteen patients enrolled to date in cohort 4 of enact (all oral induction regimen); topline interim data expected q3 2022 –
MTNB Ratings Summary
MTNB Quant Ranking